Does Benign Prostatic Hyperplasia Progress Over Time?

Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate gland that commonly affects aging men. While BPH itself is not malignant and does not increase the risk of prostate cancer, the prostate tissue involved in BPH can—and often does—continue to grow over time. This progressive enlargement is driven by hormonal changes, particularly the accumulation of dihydrotestosterone (DHT) within prostate stromal and epithelial cells, along with age-related alterations in growth factor signaling and stromal-epithelial interactions.

Clinically, prostate volume tends to increase gradually with advancing age. Longitudinal studies show that men with moderate-to-severe BPH may experience an average annual prostate volume increase of 1–2 mL, though individual rates vary significantly based on genetic predisposition, metabolic health, and lifestyle factors. Importantly, symptom severity does not always correlate directly with gland size; some men with large prostates remain asymptomatic, while others develop bothersome lower urinary tract symptoms (LUTS)—such as urinary frequency, nocturia, weak stream, or incomplete bladder emptying—even with only modest enlargement.

Without intervention, BPH progression can lead to complications including acute urinary retention, recurrent urinary tract infections, bladder stone formation, and, in rare cases, chronic kidney injury due to prolonged bladder outlet obstruction. Medical management—including alpha-blockers, 5-alpha-reductase inhibitors (e.g., finasteride or dutasteride), or newer agents like phosphodiesterase-5 inhibitors—can slow growth or reduce prostate volume, particularly in men with larger glands and elevated prostate-specific antigen (PSA) levels. Surgical options, such as transurethral resection of the prostate (TURP) or laser enucleation, provide definitive tissue removal for patients with refractory symptoms or complications.

Regular urologic evaluation—including digital rectal examination, PSA testing, and symptom scoring (e.g., IPSS)—is recommended for men aged 50 and older, or earlier for those with risk factors such as family history or African ancestry. Early detection and tailored management help mitigate disease progression and preserve urinary function and quality of life.